达拉图穆马
医学
淀粉样变性
免疫球蛋白轻链
淀粉样变性
不利影响
内科学
心力衰竭
多发性骨髓瘤
单克隆
抗体
肿瘤科
单克隆抗体
免疫学
来那度胺
作者
Charlotte Gran,Gösta Gahrton,Evren Alici,Hareth Nahi
摘要
Abstract Immunoglobulin light‐chain amyloidosis ( AL ) affects multiple organs, most prominently the kidney and the heart. Renal and cardiac impairment are both associated with poor prognosis and most patients die as a consequence of renal or cardiac failure. Monoclonal antibodies such as daratumumab (human IgG1 anti‐ CD 38) and elotuzumab (anti‐ SLAMF 7) have shown promising efficacy for the treatment of relapsed and refractory multiple myeloma. In this case report we show 2 patients with severe AL , one with severe heart failure and one with heart and renal failure, undergoing treatment with daratumumab. Both patients showed a rapid decrease in FLC in response to daratumumab infusions, with few associated adverse events. Using therapeutic CD 38 antibodies as a front‐line treatment for AL could induce rapid responses while maintaining a tolerable safety profile in these ultra‐fragile patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI